

**UNITED STATES OF AMERICA
BEFORE THE
SECURITIES AND EXCHANGE COMMISSION**

May 15, 2020

In the Matter of QIAGEN N.V.

ORDER GRANTING EXEMPTIONS FROM
SECTION 14(D)(5) OF THE EXCHANGE ACT
AND EXCHANGE ACT RULES 14D-4, 14D-7,
14D-11(C), (D) AND (E), 14E-1(B) AND (D)
AND 14E-5

Thermo Fisher Scientific Inc. submitted a letter dated May 15, 2020, requesting that the Securities and Exchange Commission (“Commission”) grant exemptions from Section 14(d)(5) of the Exchange Act and Exchange Act Rules 14d-4, 14d-7, 14d-11(c), (d) and (e), 14e-1(b) and (d) and 14e-5 for the transaction described in its letter (“Request”).

Based on the representations and the facts presented in the Request, and subject to the terms and conditions described in the letter from the Division of Corporation Finance dated May 15, 2020, it is ORDERED that the request for exemptions from Exchange Act Section 14(d)(5) and Exchange Act Rules 14d-4, 14d-7, 14d-11(c), (d) and (e), 14e-1(b) and (d) and 14e-5 is hereby granted.

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority.

Vanessa A. Countryman
Secretary